Borhane Slama

1.9k total citations
29 papers, 240 citations indexed

About

Borhane Slama is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Borhane Slama has authored 29 papers receiving a total of 240 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 8 papers in Genetics and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Borhane Slama's work include Lymphoma Diagnosis and Treatment (6 papers), Multiple Myeloma Research and Treatments (5 papers) and Acute Myeloid Leukemia Research (4 papers). Borhane Slama is often cited by papers focused on Lymphoma Diagnosis and Treatment (6 papers), Multiple Myeloma Research and Treatments (5 papers) and Acute Myeloid Leukemia Research (4 papers). Borhane Slama collaborates with scholars based in France, Italy and United States. Borhane Slama's co-authors include Daniel Birnbaum, Norbert Vey, Anne Murati, Christine Arnoulet, Emilie Coppin, D. Verrot, Nadine Carbuccia, Jérôme Rey, Julien Mozziconacci and O. Gisserot and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Borhane Slama

27 papers receiving 237 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Borhane Slama France	7	147	132	91	51	25	29	240
Miriam Hobbs United States	7	139 0.9×	75 0.6×	129 1.4×	24 0.5×	80 3.2×	26	225
Melania Carlisi Italy	10	105 0.7×	94 0.7×	74 0.8×	19 0.4×	68 2.7×	38	268
Nanna Sulai United States	8	223 1.5×	214 1.6×	140 1.5×	35 0.7×	29 1.2×	10	301
Stacey Kalambakas United States	9	69 0.5×	136 1.0×	163 1.8×	18 0.4×	60 2.4×	17	295
Damien Luque Paz France	10	188 1.3×	220 1.7×	132 1.5×	87 1.7×	22 0.9×	35	329
Alexander Sternberg United Kingdom	7	203 1.4×	107 0.8×	68 0.7×	22 0.4×	38 1.5×	14	278
Kaddour Chabane France	10	128 0.9×	126 1.0×	86 0.9×	52 1.0×	25 1.0×	17	242
Isabelle A. van Zeventer Netherlands	8	211 1.4×	166 1.3×	42 0.5×	24 0.5×	17 0.7×	16	279
Carlos E. Bueso-Ramos United States	6	149 1.0×	171 1.3×	109 1.2×	27 0.5×	73 2.9×	12	334
U. Wandl Germany	10	250 1.7×	161 1.2×	33 0.4×	88 1.7×	72 2.9×	26	343

Countries citing papers authored by Borhane Slama

Since Specialization

Citations

This map shows the geographic impact of Borhane Slama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Borhane Slama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Borhane Slama more than expected).

Fields of papers citing papers by Borhane Slama

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Borhane Slama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Borhane Slama. The network helps show where Borhane Slama may publish in the future.

Co-authorship network of co-authors of Borhane Slama

This figure shows the co-authorship network connecting the top 25 collaborators of Borhane Slama. A scholar is included among the top collaborators of Borhane Slama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Borhane Slama. Borhane Slama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hulin, Cyrille, Jérôme Lambert, Salomon Manier, et al.. (2024). Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).. Journal of Clinical Oncology. 42(16_suppl). 7501–7501. 1 indexed citations

Noël, Robin, Christophe Zemmour, Thérèse Aurran‐Schleinitz, et al.. (2023). A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma. Hematology. 28(1). 2207948–2207948.

Cheminant, Morgane, Sylvain Carras, Julie Bruneau, et al.. (2023). KILT: A RANDOMIZED NON‐COMPARATIVE PHASE II LYSA STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA. Hematological Oncology. 41(S2). 838–839.

Dartigeas, Caroline, et al.. (2022). FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL. SHILAP Revista de lepidopterología. 4(3). 65–74. 6 indexed citations

Cartron, Guillaume, Emmanuel Bachy, Hervé Tilly, et al.. (2022). Subcutaneous rituximab induction followed by short rituximab maintenance to improve progression-free survival in patients with low-tumor burden follicular lymphoma: Final results of FLIRT phase III trial, a LYSA study.. Journal of Clinical Oncology. 40(16_suppl). 7512–7512. 1 indexed citations

Groh, Matthieu, Laura Venditti, Émilie Chalayer, et al.. (2021). FIP1L1-PDGFRA-Associated Hypereosinophilic Syndrome as a Treatable Cause of Watershed Infarction. Stroke. 52(10). e605–e609. 5 indexed citations

Terpos, Evangelos, Borhane Slama, Renato Zambello, et al.. (2020). Real-World Evidence of the Use of Carfilzomib Among Multiple Myeloma Patients with at Least One Prior Therapy across 10 European Countries and Israel. Blood. 136(Supplement 1). 38–39. 4 indexed citations

Rodeghiero, Francesco, et al.. (2018). Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia. Journal of Hematology. 7(3). 87–95. 3 indexed citations

Haïoun, Corinne, Camille Laurent, Fabien Le Bras, et al.. (2018). Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL): The French Lymphoma Study Association (LYSA) registry data.. Journal of Clinical Oncology. 36(15_suppl). 7554–7554. 2 indexed citations

10.

Viallard, Jean‐François, Philippe Agapé, Vincent Barlogis, et al.. (2016). Treatment with Hizentra in patients with primary and secondary immunodeficiencies: a real-life, non-interventional trial. BMC Immunology. 17(1). 34–34. 5 indexed citations

11.

Debourdeau, P., Catherine Meuleman, Ghislaine Dufaître, et al.. (2015). Méthodes d’élaboration des recommandations pour la pratique clinique (RPC) et fonctionnement de la plate forme cœur vaisseaux cancer (PTF-CVC) dans l’inter3C Vaucluse pays d’Arles. Bulletin du Cancer. 102(11). 932–939. 2 indexed citations

12.

Brecqueville, Mandy, Jérôme Rey, François Bertucci, et al.. (2012). Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes and Cancer. 51(8). 743–755. 113 indexed citations

13.

Leleu, Xavier, Philippe Rodon, Cyrille Hulin, et al.. (2011). Final Analysis of MELISSE, a Large Multicentric Observational Study to Determine Risk Factors of Venous Thromboembolism in Patients with Multiple Myeloma Treated with Immunomodulator Drugs. Blood. 118(21). 1235–1235. 1 indexed citations

14.

Sibon, David, Giovanna Cannas, Fiorenza Barraco, et al.. (2010). Lenalidomide (LEN) In Lower-Risk Myelodysplastic Syndromes (MDS) with Karyotypes Other Than Deletion 5q and Refractory to Erythropoiesis-Stimulating Agents (ESAs). Blood. 116(21). 4002–4002. 2 indexed citations

15.

Fouchardière, Christelle de la, R. Largillier, Anne‐Claire Hardy‐Bessard, et al.. (2009). Docetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients: results of the phase II GINECO trial CAPYTTOLE. Annals of Oncology. 20(12). 1959–1963. 10 indexed citations

16.

Dadban, A., Borhane Slama, A. Azzedine, & G. Lepeu. (2008). Widespread granuloma annulare and Hodgkin's disease. Clinical and Experimental Dermatology. 33(4). 465–468. 18 indexed citations

17.

Guastalla, Jean‐Paul, R. Largillier, J.-F. Geay, et al.. (2006). Docetaxel (Do) and liposomal pegylated doxorubicin in metastatic breast cancer (MBC) patients (pts): The French GINECO group experience. Journal of Clinical Oncology. 24(18_suppl). 10589–10589. 1 indexed citations

18.

Murati, Anne, Christine Arnoulet, Mårina Lafage‐Pochitaloff, et al.. (2005). Dual lympho-myeloproliferative disorder in a patient with t(8;22) with BCR-FGFR1 gene fusion. International Journal of Oncology. 26(6). 1485–92. 27 indexed citations

19.

Slama, Borhane, et al.. (1978). Prophylactic lithium treatment of drug abuse.. PubMed. 20(1). 70–2. 2 indexed citations

20.

Slama, Borhane, et al.. (1976). [Pyrithioxin (Encephabol) in the treatment of patients with organic psychosyndrom in involution. Clinical, EEG and experimental psychological study (author's transl)].. PubMed. 72(1). 14–23. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact